BSX
波士頓科學 BOSTON SCIENTIFIC CORP
-0.82 (-1.87%)43.09USD7.9M成交股數62.4B市值17.4本益比(近四季)3.0股價營收比+7.5%營收年增(近四季)2026-10-28下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 5.4B+8% | 5.2B+12% | 5.3B+26% | 5.1B+23% | 5.1B+31% | 4.7B+25% | 4.2B+19% | 4.1B+14% | 3.9B | 3.7B | 3.5B | 3.6B |
| 營業成本 | 1.6B | 1.6B | 1.6B | 1.5B | 1.6B | 1.5B | 1.3B | 1.3B | 1.2B | 1.1B | 1.1B | 1.1B |
| 毛利 | 3.8B+12% | 3.6B+13% | 3.7B+27% | 3.5B+24% | 3.4B+29% | 3.2B+24% | 2.9B+19% | 2.9B+12% | 2.6B | 2.6B | 2.4B | 2.5B |
| 毛利率 | 70.7% | 69.5% | 69.6% | 69.9% | 67.7% | 68.8% | 68.8% | 69.2% | 68.7% | 69.2% | 68.8% | 70.6% |
| 研發費用 | 554M | 516M | 569M | 514M | 526M | 443M | 407M | 383M | 366M | 362M | 356M | 359M |
| 銷售管理費用 | 1.8B | 1.8B | 1.8B | 1.7B | 1.7B | 1.6B | 1.6B | 1.4B | 1.4B | 1.4B | 1.2B | 1.4B |
| 營業利益 | 1.2B+44% | 1.1B+20% | 825M+13% | 1.0B+102% | 819M+21% | 921M+58% | 733M+6% | 520M+1% | 675M | 584M | 693M | 514M |
| 營業利益率 | 21.6% | 21.2% | 15.6% | 20.7% | 16.2% | 19.8% | 17.4% | 12.6% | 17.5% | 15.7% | 19.6% | 14.3% |
| 稅後淨利 | 905M+14% | 1.3B+99% | 670M+43% | 755M+134% | 795M+61% | 672M+33% | 468M-7% | 322M+19% | 493M | 504M | 504M | 270M |
| 淨利率 | 16.6% | 25.7% | 12.7% | 14.9% | 15.7% | 14.4% | 11.1% | 7.8% | 12.8% | 13.5% | 14.3% | 7.5% |
| 稀釋 EPS | 0.61+15% | 0.90+100% | 0.45+41% | 0.51+132% | 0.53+61% | 0.45+32% | 0.32-6% | 0.22+22% | 0.33 | 0.34 | 0.34 | 0.18 |
| 稀釋股數 | 1.47B | 1.50B | 1.49B | 1.50B | 1.49B | 1.49B | 1.49B | 1.48B | 1.48B | 1.46B | 1.48B | 1.46B |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 539M | 1.5B | 2.0B | 1.3B | 534M | 725M | 2.5B | 2.9B | 2.3B | 865M | 952M | 426M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | 3.2B | 3.1B | 2.9B | 2.9B | 2.9B | 2.9B | 2.8B | 2.6B | 2.6B | 2.5B | 2.4B | 2.3B |
| 總資產 | 45.2B | 44.4B | 43.7B | 42.7B | 41.6B | 40.1B | 38.1B | 37.1B | 36.7B | 35.1B | 34.0B | 33.6B |
| 有息負債 | 10.9B | 11.0B | 11.1B | 11.1B | 11.1B | 10.5B | 9.2B | 9.0B | 9.5B | 8.6B | 8.4B | 8.5B |
| 總負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 股東權益 | 24.9B | 25.9B | 24.2B | 23.4B | 22.4B | 22.2B | 20.7B | 20.4B | 19.9B | 19.3B | 18.9B | 18.2B |
| 負債比 | – | – | – | – | – | – | – | – | – | – | – | – |
| 淨現金(現金 − 有息負債) | −10.4B | −9.5B | −9.2B | −9.8B | −10.6B | −9.8B | −6.7B | −6.1B | −7.2B | −7.7B | −7.4B | −8.1B |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 348M-36% | – | – | – | 541M | – | – | 164M | – | – | – |
| 資本支出 | – | 177M | – | – | – | 187M | – | – | 179M | – | – | – |
| 自由現金流 | – | 171M-52% | – | – | – | 354M | – | – | −15.0M | – | – | – |
| 折舊攤銷 | – | 351M | – | – | – | 325M | – | – | 304M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | 0.00 | – | – | – |
| 自由現金流率 | – | 3.3% | – | – | – | 7.6% | – | – | -0.4% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 20.1B
| Cardiovascular | 13.3B | 66.0% | +23.2% |
|---|---|---|---|
| Medsurg | 6.8B | 34.0% | +13.9% |
地區2025 年度 · 23.1B
| 美國 | 12.9B | 55.8% | +26.0% |
|---|---|---|---|
| 歐洲中東非洲 | 3.5B | 15.0% | +6.9% |
| 亞太 | 3.1B | 13.4% | +14.7% |
| Emerging Markets | 3.0B | 12.9% | +11.4% |
| Latin Americaand Canada | 678M | 2.9% | +8.7% |
| 美國以外 小計 | 7.2B | 31.3% | +10.3% |
產品／服務2025 年度 · 9.2B
| Global Urologyand Pelvic Health Reporting Unit | 2.7B | 29.5% | +23.1% |
|---|---|---|---|
| Cardiac Rhythm Management | 2.3B | 25.4% | +2.3% |
| Watchman | 2.0B | 21.3% | +29.2% |
| Global Neuromodulation Nm Reporting Unit | 1.2B | 13.0% | +8.4% |
| Interventional Oncology Embolization | 996M | 10.8% | +16.4% |
| Interventional Cardiology Vascular Therapies 小計 | 4.6B | 50.5% | +10.5% |
| Electrophysiology EP 小計 | 3.3B | 36.2% | +74.6% |
| Global Endoscopy Endo Reporting Unit 小計 | 2.9B | 31.7% | +8.5% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 20.1B | +19.9% | 2.9B | 14.4% | 1.94 | 3.7B |
| FY2024 | 16.7B | +17.6% | 1.8B | 11.0% | 1.25 | 2.6B |
| FY2023 | 14.2B | +12.3% | 1.6B | 11.2% | 1.07 | 1.8B |
| FY2022 | 12.7B | +6.7% | 698M | 5.5% | 0.45 | 938M |
| FY2021 | 11.9B | +19.9% | 1.0B | 8.8% | 0.69 | 1.3B |
| FY2020 | 9.9B | -7.7% | −82.0M | -0.8% | -0.08 | 1.1B |
| FY2019 | 10.7B | +9.3% | 4.7B | 43.8% | 3.33 | 1.4B |
| FY2018 | 9.8B | – | 1.7B | 17.0% | 1.19 | −6.0M |